Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1997-08-01
2000-12-05
Russel, Jeffrey E.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 21, 530300, 530324, 530858, A61K 3802, A61K 3817, C07K 200, C07K 14435
Patent
active
061567264
ABSTRACT:
A novel class of peptides selectively block class E voltage-gated calcium channels. The class is exemplified by HG peptides such as HG-1, which is isolated from the venom-producing cells of the tarantula Hysterocrates gigas. Also disclosed are methods of producing blocking class E channels using the peptides. HG peptides have utility, for example, in inhibiting oxytocin release and for use as anticonvulsants.
REFERENCES:
Ferrendelli, J.A., "Pharmacology of Antiepileptic Drugs," Epilepsia, 28 (Suppl. 3):S14-S16 (1987).
Jackson, H.C. and Scheideler, M.A., "Behavioural and Anticonvulsant Effects of Ca.sup.2+ Channel Toxins in DBA/2 mice," Psychopharmacology, 126:85-90 (1996).
Keirse, M.J.N.C., "New Perspectives for the Effective Treatment of Preterm Labor", Am. J. Obstet. Gynecol., 173(2):618-628 (1995).
Krapcho, K.J., et al., "Characterization and Cloning of Insecticidal Peptides from the Primitive Weaving Spider Diguetia canities," Insect. Biochem. Molec. Biol., 25(9):991-1000 (1995).
Kupferberg, H.J., "Antiepileptic Drug Development Program: A Cooperative Effort of Government and Industry," Epilepsia, 30 (Suppl. 1):S51-S56 (1989).
Macdonald, R.L., and Kelly, K.M., "Antiepileptic Drug Mechanisms of Action," Epilepsia, 34 (Suppl. 5):S1-S8 (1993).
McCombs, J., "Update on Tocolytic Therapy", Ann. Pharmacother., 29:515-522 (1995).
McNamara, J.O., "Development of New Pharmacological Agents for Epilepsy: Lessons from the Kindling Model," Epilepsia., 30 (Suppl. 1):S13-S18 (1989).
Wang, G., et al., "Role of Q-Type Ca.sup.2+ Channels in Vasopressin Secretion from Neurohypophysial Terminals of the Rat," J. Physiol. (Lond.), 502 (Pt. 2):351-363 (1997).
Newcomb,Robert et al., "SNX-325, A novel Calcium Antagonist from the Spider Segestria florentina," Biochemistry 34: 8341-8347 (1995).
Piser, Timothy M., et al., ".omega.-Grammotoxin SIA Blocks Multiple, Voltage-Gated, Ca.sup.2+ Channel subtypes in Cultured Rat Hippocampal Neurons," Mol Pharmacol 48(1): 131-139 (1995).
Bowersox Stephen Scott
Cong Ruth L.
Dean Robin
Hopkins William F.
Miljanich George P.
Elan Pharmaceuticals Inc.
Gorthey LeeAnn
Russel Jeffrey E.
Stratford Carol A.
LandOfFree
Voltage-gated calcium channel antagonist and method does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Voltage-gated calcium channel antagonist and method, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Voltage-gated calcium channel antagonist and method will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-961787